Affecting over 1.5 million people across the world, Parkinson’s disease is a progressive neurological condition. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson´s disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson´s disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms.
Today is World Parkinson’s Disease Day – a day for raising awareness and for educating the community of its causes, symptoms and the medical/surgical treatment methods available. The first World Parkinson’s Disease Day, which commemorated the birthday of Dr James Parkinson, also saw the launch of the EPDA’s Charter for People with Parkinson’s. More than 30 Parkinson’s organisations around the world united on the same day to support the Charter.
To support the work of researchers in industry and academia involved in drug discovery for Parkinson’s Disease, the Royal Society of Chemistry recently published Emerging Drugs and Targets for Parkinson’s Disease, edited by Ana Martinez and Carmen Gil.
“Altogether, I can recommend this volume of the excellent RSC Drug Discovery Series to medicinal chemists, (chemical) biologists and pharmacologists interested in drug development for Parkinson’s Disease” Prof. Christa E. Muller, ChemMedChem
Find out more about the RSC Drug Discovery Series at http://rsc.li/drug-discoveryor email framer@rsc.org
